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components of CP or treated as covariates. Because CP are active both on organiza-
tional (units) and individual (patients) level, a two-arm cluster Randomized Controlled 
Trial with hospitals and long-term rehabilitation facilities as randomization units was 
designed in phase II. Fourteen units were randomized either to arm 1 (CP) or to arm 
2 (usual care) including 238 patients per group. The primary outcome measure was 
mortality, the CP were also analyzed with key quality indicators. The trial has been 
successfully performed (phase III) and in-hospital mortality has been reduced (OR = 
0.10; P = 0.04). Because the adjusted results are not available yet, it was not possible 
to identify the active components of the CP and therefore phase IV has not been 
performed. CONCLUSIONS: Even if the results are still partial, it seems possible to 
apply this framework to the study of CP. 
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OBJECTIVES: 1) Compare efﬁ cacy and safety of sitagliptin and vildagliptin in type 
2 diabetes; and 2) Examine prescription of concomitant oral hypoglycemic agents 
(OHAs) and insulin. METHODS: We conducted a retrospective database study, 
drawing information from all patients treated at Singapore Health Services cluster 
institutions over 1.5-year study period. Inclusion criteria: HbA1C >7%, naive to 
gliptins, and remained on gliptin for at least 90 days (from pharmacy records). Exclu-
sion criteria: patients who switched gliptins, and HbA1c not tested within 10 days of 
exit timepoint. IRB approval was obtained. RESULTS: Sitagliptin (n = 340) and 
vildagliptin (n = 92) patients met inclusion and exclusion criteria. General demograph-
ics matched at baseline (all P > 0.05). Mean duration of gliptin treatment 242 days 
(sitagliptin) versus 220 days (vildagliptin) (P = 0.944). Mean baseline HbA1c matched 
at 8.95% (sitagliptin) versus 9.18% (vildagliptin) (P = 0.15). At exit, sitagliptin arm 
demonstrated absolute HbA1c reduction of −0.643% versus vildagliptin −0.728% (P 
= 0.61); percentage reduction in HbA1c was sitagliptin −6.55% versus vildagliptin 
−7.589% (p = 0.44). Subgroup analyses of a) patients with entry HbA1c >8%; b) 
stratiﬁ cation of outcome by dose of gliptin; and c) addition or discontinuation of OHA 
from baseline all did not demonstrate statistically signiﬁ cant difference. Majority of 
patients were not on maximal OHA doses at gliptin initiation, however total daily 
doses of OHAs was not signiﬁ cantly different at exit versus baseline for both arms. 
Almost 90% of patients in both groups received multiple OHAs for diabetes control. 
Change in creatinine clearance was comparable in both arms. Safety endpoints micro-
albuminuria/creatinine ratio, average % weight change and incidence of pancreatitis 
were not signiﬁ cantly different between both arms (all P > 0.05). Five sitagliptin 
patients required hospital admission for severe hypoglycemia vs 0 vildagliptin patients. 
CONCLUSIONS: We present our initial ﬁ ndings that vildagliptin is non-inferior to 
sitagliptin in HbA1c-lowering efﬁ cacy. Both products are well-tolerated without sig-
niﬁ cant differences in safety endpoints save severe hypoglycemia in sitagliptin arm. 
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OBJECTIVES: To evaluate the long-term health outcomes associated with Liraglutide 
1.2 and 1.8 mg versus Glimepiride 4 mg all combined with Metformin in Asian 
patients with type 2 diabetes (T2D). METHODS: A published and validated computer 
simulation model of diabetes (CORE Diabetes Model) was used to make the projection 
of long-term health outcomes (30 years). Simulated cohorts and treatment effects were 
derived from 928 T2D patients in the NCT00614120 trial held in China, South Korea 
and India. HbA1C was signiﬁ cantly reduced in Liraglutide 1.2 mg, Liraglutide 1.8 mg, 
and Glimepiride groups (−1.3%, −1.4%, and −1.3% respectively). Liraglutide treat-
ments led to greater reduction in Body Mass Index and systolic blood pressure versus 
Glimepride. No major hypoglycemia was reported in Liraglutide groups, while the 
rate of major hypoglycemia for Glimepride was 0.029 per patient-year. The rate of 
minor hypoglycemia was lower in Liraglutide groups than Glimepiride. An annual 
discounting rate of 3% was used for health and cost outcomes. One-way sensitivity 
analysis was performed. RESULTS: The treatments of Liraglutide compared with 
Glimepiride were projected to reduce the cumulative incidences of diabetes complica-
tions and improve long term health outcomes for patients with T2D. For Liraglutide 
1.2 mg, the cumulative incidences of background retinopathy, end stage renal disease, 
ulcer, and congestive heart failure event were reduced 0.20%, 0.086%, 0.020% and 
0.53% respectively, discounted life expectancy was increased 0.058 year and quality 
adjusted life-years (QALY) was increased 0.11 QALY. For Liraglutide 1.8mg, the 
incidences reduction were 0.61%, 0.12%, 0.34% and 0.63% respectively, discounted 
life expectancy was improved 0.051 year, and 0.107 QALY. CONCLUSIONS: Lira-
glutide 1.2 mg and 1.8 mg therapy could delay the onset of diabetes complications 
and reduced related cumulative incidences over patient lifetimes compared with 
Glimepiride. It improved the life expectancy and quality adjusted life expectancy in 
Asian patients with T2D. 
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OBJECTIVES: To address effects of extended-release versus immediate-release glipi-
zide on glucose control, insulin secretion, and compliance. METHODS: We included 
parallel randomized trials and cohort studies (only for compliance assessment) com-
paring extended-release versus immediate-release glipizide for type 2 diabetes. We 
searched Medline, EMBASE, the Cochrane Library, and Chinese Biomedical database, 
screened reference lists, and contacted pharmaceutical company. We pooled data using 
random-effect model and explored heterogeneity by pre-speciﬁ ed hypotheses. 
RESULTS: Sixteen trials involving 1062 patients and two retrospective cohort studies 
of 13,452 patients were included. Trials are of inadequate quality. No trials reported 
patient-important outcomes. The reduction of fasting plasma glucose from the baseline 
appeared larger in extended-release than immediate-release glipizide (mean difference 
−0.30 mmol/L, 95% CI −0.57 to −0.03). The reduction was not signiﬁ cant different 
between two drugs in HbA1c (−0.03%, −0.20% to 0.15%) and 2-hour postprandial 
plasma glucose (−0.28 mmol/L, −1.12 to 0.55). Extended-release glipizide appeared 
to reduce insulin secretion from the baseline, whereas immediate-release formulation 
increased the secretion (fasting insulin: −0.86 vs. 0.28 μIU/ml; 2-hour postprandial 
insulin: −2.94 vs. 0.24 μIU/ml). Patients administering extended-release glipizide had 
less hypoglycemia (Peto odds ratio 0.26, 95% CI 0.08 to 0.81) and lower missed 
dosing (Peto odds ratio 10.24, 95%CI 5.22 to 20.08). The cohort studies showed 
results in compliance consistent with trials. CONCLUSIONS: The two drugs may 
have comparable effects on glucose control. Extended-release glipizide might achieve 
glucose control with decreased insulin secretion, and fewer hypoglycemic episodes. 
The ﬁ ndings are inconclusive due to inadequate study quality, short follow-up, and 
unavailability of patient important outcomes. 
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OBJECTIVES: To assess overall and diabetes-related medical service costs associated 
with pioglitazone (PIO) and sulfonylureas (SU) treatment among T2DM patients. 
METHODS: This is a retrospective cohort study based on electronic medical records 
(January 1, 2004–January 31, 2009) from the Geisinger Clinic in the Northeastern 
region of the United States. The date of the initial prescription for PIO or SU was 
denoted as the index date. Patients were required to be aged 18 years or older and 
prescribed an oral antidiabetic treatment in the 1 year prior to index. Patients with 
type 1 or gestational diabetes and prior insulin use were excluded, as were those who 
had prescriptions for the index drug in the 90 days prior. Propensity score 1:1 match-
ing and a second stage of generalized linear regression were employed to assess overall 
and diabetes-related medical service costs (pharmacy costs were not available in the 
database) in the 2 years following the index date, adjusting for patient demographics, 
baseline comorbidities, medication use, and health-care resource utilization. RESULTS: 
A total of 2758 patients, 1379 each in the PIO and SU cohorts, were analyzed. For 
both cohorts, mean age was 62 years, 46% were male, and 96% were Caucasian. The 
two cohorts were similar in terms of current smoking status and diabetes-related 
comorbidities. The unadjusted total and diabetes-related medical costs were $1258 
and $705 higher for SU versus PIO patients. After adjusting for covariates, the overall 
and diabetes-related medical service costs remained higher for patients receiving SU 
versus PIO ($8360 vs. $7400 for overall, and $5577 vs. $5238 for diabetes-related 
costs, P < 0.05 for both comparisons). CONCLUSIONS: Over a 2-year follow-up, 
patients with T2DM initiated on PIO therapy in an integrated system incurred lower 
overall and diabetes-related medical service costs than patients initiated on SU. Further 
studies describing clinical and humanistic aspects of PIO versus SU are warranted. 
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OBJECTIVES: To estimate annual health-care costs associated with hypoglycemia 
among T2DM patients initiated on oral antidiabetic drugs (OADs) in a large managed 
care cohort with managed care insurance beneﬁ ts. METHODS: T2DM patients initi-
ated on OADs were selected from the Ingenix Impact database (1999–2008). Patients 
aged 18 years or older with at least 1 year of continuous eligibility following the index 
date (the ﬁ rst OAD prescription ﬁ ll date) who were diagnosed with moderate to severe 
